Dry Powder Inhalation for Lung Delivery in Cystic Fibrosis

Pulmonary drug delivery has long been used for local and systemic administration of different medications used in acute and chronic respiratory diseases. Certain lung diseases, such as cystic fibrosis, rely heavily on chronic treatments, including targeted lung delivery. Pulmonary drug delivery possesses various physiological advantages compared to other delivery methods and is also convenient for the patient to use. However, the formulation of dry powder for pulmonary delivery proves challenging due to aerodynamic restrictions and the lower tolerance of the lung. The aim of this review is to provide an overview of the respiratory tract structure in patients with cystic fibrosis, including during acute and chronic lung infections and exacerbations. Furthermore, this review discusses the advantages of targeted lung delivery, including the physicochemical properties of dry powder and factors affecting clinical efficacy. Current inhalable drug treatments and drugs currently under development will also be discussed.

[1]  M. Martínez-García,et al.  Inhaled Colistimethate Sodium in the Management of Patients with Bronchiectasis Infected by Pseudomonas aeruginosa: A Narrative Review of Current Evidence , 2022, Infection and drug resistance.

[2]  Prabhanjan S. Giram,et al.  Progress on Thin Film Freezing Technology for Dry Powder Inhalation Formulations , 2022, Pharmaceutics.

[3]  Z. Cui,et al.  Pharmaceutical dry powders of small molecules prepared by thin-film freezing and their applications - A focus on the physical and aerosol properties of the powders. , 2022, International journal of pharmaceutics.

[4]  K. Tahara,et al.  Dry Powder Inhalers for Proteins Using Cryo-Milled Electrospun Polyvinyl Alcohol Nanofiber Mats , 2022, Molecules.

[5]  E. Schneider-Futschik,et al.  Ivacaftor Alters Macrophage and Lymphocyte Infiltration in the Lungs Following Lipopolysaccharide Exposure. , 2022, ACS pharmacology & translational science.

[6]  Shirui Mao,et al.  Spray Dried Inhalable Ivacaftor Co-Amorphous Microparticle Formulations with Leucine Achieved Enhanced In Vitro Dissolution and Superior Aerosol Performance. , 2022, International journal of pharmaceutics.

[7]  Jesse Zhu,et al.  The future of dry powder inhaled therapy: Promising or discouraging for systemic disorders? , 2022, International Journal of Pharmaceutics.

[8]  E. Schneider-Futschik,et al.  Anti-Inflammatory Influences of Cystic Fibrosis Transmembrane Conductance Regulator Drugs on Lung Inflammation in Cystic Fibrosis , 2021, International journal of molecular sciences.

[9]  L. Moroni,et al.  Electrospinning for drug delivery applications: A review. , 2021, Journal of controlled release : official journal of the Controlled Release Society.

[10]  H. Chan,et al.  Dry Powder Pharmaceutical Biologics for Inhalation Therapy. , 2021, Advanced drug delivery reviews.

[11]  Jasmim Leal,et al.  Aerosolizable siRNA-Encapsulated Solid Lipid Nanoparticles Prepared by Thin-film Freeze-Drying for Potential Pulmonary Delivery. , 2021, International journal of pharmaceutics.

[12]  Birendra Chaurasiya,et al.  Dry Powder for Pulmonary Delivery: A Comprehensive Review , 2020, Pharmaceutics.

[13]  J. Mortensen,et al.  Inhaled dry powder alginate oligosaccharide in cystic fibrosis: a randomised, double-blind, placebo-controlled, crossover phase 2b study , 2020, ERJ Open Research.

[14]  D. McAuley,et al.  Airway Inflammation and Host Responses in the Era of CFTR Modulators , 2020, International journal of molecular sciences.

[15]  E. Schneider-Futschik,et al.  Metabolomic Description of Ivacaftor Elevating Polymyxin B Mediated Antibacterial Activity in Cystic Fibrosis Pseudomonas aeruginosa. , 2020, ACS pharmacology & translational science.

[16]  Michelle Condren,et al.  Elexacaftor-Tezacaftor-Ivacaftor: The First Triple-Combination Cystic Fibrosis Transmembrane Conductance Regulator Modulating Therapy. , 2020, The journal of pediatric pharmacology and therapeutics : JPPT : the official journal of PPAG.

[17]  M. Lopes-Pacheco.  CFTR Modulators: The Changing Face of Cystic Fibrosis in the Era of Precision Medicine , 2020, Frontiers in Pharmacology.

[18]  C. Teneback,et al.  Efficacy and safety of the elexacaftor plus tezacaftor plus ivacaftor combination regimen in people with cystic fibrosis homozygous for the F508del mutation: a double-blind, randomised, phase 3 trial , 2019, The Lancet.

[19]  L. Lands,et al.  Elexacaftor-Tezacaftor-Ivacaftor for Cystic Fibrosis with a Single Phe508del Allele. , 2019, The New England journal of medicine.

[20]  E. Schneider-Futschik,et al.  Emerging Cystic Fibrosis Transmembrane Conductance Regulator Modulators as New Drugs for Cystic Fibrosis: A Portrait of in Vitro Pharmacology and Clinical Translation. , 2019, ACS pharmacology & translational science.

[21]  W. Carroll,et al.  Understanding Dry Powder Inhalers: Key Technical and Patient Preference Attributes , 2019, Advances in Therapy.

[22]  E. Sorscher,et al.  Making precision medicine personal for cystic fibrosis , 2019, Science.

[23]  Yuguo Li,et al.  Recognition of aerosol transmission of infectious agents: a commentary , 2019, BMC Infectious Diseases.

[24]  T. Minko,et al.  Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers , 2019, Journal of controlled release : official journal of the Controlled Release Society.

[25]  Ahmad B. Albadarin,et al.  Spray drying of pharmaceuticals and biopharmaceuticals: Critical parameters and experimental process optimization approaches , 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[26]  Thomas B. Clarke,et al.  Colistin kills bacteria by targeting lipopolysaccharide in the cytoplasmic membrane , 2018, eLife.

[27]  F. van Goor,et al.  VX‐445–Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis and One or Two Phe508del Alleles , 2018, The New England journal of medicine.

[28]  M. Jennings,et al.  Cystic Fibrosis: Translating Molecular Mechanisms into Effective Therapies. , 2018, Annals of the American Thoracic Society.

[29]  R. Sierra,et al.  Aminoglycoside ribosome interactions reveal novel conformational states at ambient temperature , 2018, bioRxiv.

[30]  D. Hoyer,et al.  Sputum Active Polymyxin Lipopeptides: Activity against Cystic Fibrosis Pseudomonas aeruginosa Isolates and Their Interactions with Sputum Biomolecules , 2018, ACS infectious diseases.

[31]  R. Ambrus,et al.  Physicochemical stability and aerosolization performance of dry powder inhalation system containing ciprofloxacin hydrochloride , 2018, Journal of Pharmaceutical and Biomedical Analysis.

[32]  Waseem Kaialy,et al.  Agglomerated novel spray-dried lactose-leucine tailored as a carrier to enhance the aerosolization performance of salbutamol sulfate from DPI formulations , 2017, Drug Delivery and Translational Research.

[33]  J. Ohar,et al.  Peak Inspiratory Flow Rate in Chronic Obstructive Pulmonary Disease: Implications for Dry Powder Inhalers. , 2017, Journal of aerosol medicine and pulmonary drug delivery.

[34]  T. Radtke,et al.  Physical exercise training for cystic fibrosis. , 2017, The Cochrane database of systematic reviews.

[35]  D. Serrano,et al.  Nebulised antibiotherapy: conventional versus nanotechnology-based approaches, is targeting at a nano scale a difficult subject? , 2017, Annals of translational medicine.

[36]  J. Ribeiro,et al.  Personalized or Precision Medicine? The Example of Cystic Fibrosis , 2017, Front. Pharmacol..

[37]  E. Nash,et al.  Ease of use of tobramycin inhalation powder compared with nebulized tobramycin and colistimethate sodium: a crossover study in cystic fibrosis patients with pulmonary Pseudomonas aeruginosa infection , 2017, Therapeutic advances in respiratory disease.

[38]  P. Rytilä,et al.  Budesonide/Formoterol Easyhaler®: Performance Under Simulated Real-Life Conditions , 2017, Pulmonary Therapy.

[39]  Sheena D Brown,et al.  Keep them breathing: Cystic fibrosis pathophysiology, diagnosis, and treatment , 2017, JAAPA : official journal of the American Academy of Physician Assistants.

[40]  L. Lands,et al.  Inhaled dry powder mannitol in children with cystic fibrosis: A randomised efficacy and safety trial. , 2017, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[41]  Wouter A. A. de Steenhuijsen Piters,et al.  The microbiota of the respiratory tract: gatekeeper to respiratory health , 2017, Nature Reviews Microbiology.

[42]  S. McColley,et al.  Lumacaftor/Ivacaftor Treatment of Patients with Cystic Fibrosis Heterozygous for F508del‐CFTR , 2017, Annals of the American Thoracic Society.

[43]  G. Srinivasan,et al.  ADVANCEMENTS IN DRY POWDER INHALER , 2017 .

[44]  J. Li,et al.  Can Cystic Fibrosis Patients Finally Catch a Breath With Lumacaftor/Ivacaftor? , 2017, Clinical pharmacology and therapeutics.

[45]  C. Janson,et al.  Difference in resistance to humidity between commonly used dry powder inhalers: an in vitro study , 2016, npj Primary Care Respiratory Medicine.

[46]  Phillip J. Bergen,et al.  An "Unlikely" Pair: The Antimicrobial Synergy of Polymyxin B in Combination with the Cystic Fibrosis Transmembrane Conductance Regulator Drugs KALYDECO and ORKAMBI. , 2016, ACS infectious diseases.

[47]  N. Sandler,et al.  Evaluation of inhaler handling-errors, inhaler perception and preference with Spiromax, Easyhaler and Turbuhaler devices among healthy Finnish volunteers: a single site, single visit crossover study (Finhaler) , 2016, BMJ Open Respiratory Research.

[48]  D. Price,et al.  Characteristics of patients making serious inhaler errors with a dry powder inhaler and association with asthma-related events in a primary care setting , 2016, The Journal of asthma : official journal of the Association for the Care of Asthma.

[49]  H. Dorkin,et al.  Ciprofloxacin DPI: a randomised, placebo-controlled, phase IIb efficacy and safety study on cystic fibrosis , 2015, BMJ Open Respiratory Research.

[50]  A. Samanta,et al.  Overview of milling techniques for improving the solubility of poorly water-soluble drugs , 2015 .

[51]  M. Konstan,et al.  Inflammation in cystic fibrosis lung disease: Pathogenesis and therapy. , 2015, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[52]  A. Lamprecht,et al.  Devices for Dry Powder Drug Delivery to the Lung , 2015, AAPS PharmSciTech.

[53]  H. Chrystyn,et al.  The inhalation characteristics of patients when they use different dry powder inhalers. , 2015, Journal of aerosol medicine and pulmonary drug delivery.

[54]  Y. Komase,et al.  Ease-of-use preference for the ELLIPTA® dry powder inhaler over a commonly used single-dose capsule dry powder inhaler by inhalation device-naïve Japanese volunteers aged 40 years or older , 2014, International journal of chronic obstructive pulmonary disease.

[55]  F. Lavorini.  Inhaled drug delivery in the hands of the patient. , 2014, Journal of aerosol medicine and pulmonary drug delivery.

[56]  M. Henry,et al.  A neutrophil intrinsic impairment affecting Rab27a and degranulation in cystic fibrosis is corrected by CFTR potentiator therapy. , 2014, Blood.

[57]  Umer Khan,et al.  Clinical mechanism of the cystic fibrosis transmembrane conductance regulator potentiator ivacaftor in G551D-mediated cystic fibrosis. , 2014, American journal of respiratory and critical care medicine.

[58]  H. Smyth,et al.  Evaluation of Granulated Lactose as a Carrier for DPI Formulations 1: Effect of Granule Size , 2014, AAPS PharmSciTech.

[59]  Christel C. Müller-Goymann,et al.  Nanoparticle-Mediated Pulmonary Drug Delivery: A Review , 2014, International journal of molecular sciences.

[60]  P. Tappenden,et al.  The Cost Effectiveness of Dry Powder Antibiotics for the Treatment of Pseudomonas aeruginosa in Patients with Cystic Fibrosis , 2014, PharmacoEconomics.

[61]  J. Elborn,et al.  Antibiotic and anti-inflammatory therapies for cystic fibrosis. , 2013, Cold Spring Harbor perspectives in medicine.

[62]  H. Stass,et al.  Tolerability and pharmacokinetic properties of ciprofloxacin dry powder for inhalation in patients with cystic fibrosis: a phase I, randomized, dose-escalation study. , 2013, Clinical therapeutics.

[63]  A. Chuchalin,et al.  Tobramycin inhalation powder manufactured by improved process in cystic fibrosis: the randomized EDIT trial , 2013, Current medical research and opinion.

[64]  Stefan Willmann,et al.  Inhalation of a Dry Powder Ciprofloxacin Formulation in Healthy Subjects: A Phase I Study , 2013, Clinical Drug Investigation.

[65]  G. Bellon,et al.  Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. , 2012, American journal of respiratory and critical care medicine.

[66]  G. Döring,et al.  Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study , 2012, Thorax.

[67]  D. VanDevanter,et al.  Tobramycin administered by the TOBI® Podhaler® for persons with cystic fibrosis: a review , 2011, Medical devices.

[68]  J. Weers,et al.  Development of an inhaled dry-powder formulation of tobramycin using PulmoSphere™ technology. , 2011, Journal of aerosol medicine and pulmonary drug delivery.

[69]  E. Kerem,et al.  Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life. , 2011, American journal of respiratory and critical care medicine.

[70]  Marco Lodi,et al.  Inhaler mishandling remains common in real life and is associated with reduced disease control. , 2011, Respiratory medicine.

[71]  C. Gallagher,et al.  Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study , 2011, European Respiratory Journal.

[72]  S. Rees,et al.  Principles of early drug discovery , 2011, British journal of pharmacology.

[73]  J. Clancy,et al.  Effect of VX-770 in persons with cystic fibrosis and the G551D-CFTR mutation. , 2010, The New England journal of medicine.

[74]  Jiang Chang,et al.  Electrospun nanofibrous materials for tissue engineering and drug delivery , 2010, Science and technology of advanced materials.

[75]  Raymond Lau,et al.  Effect of Particle Shape on Dry Particle Inhalation: Study of Flowability, Aerosolization, and Deposition Properties , 2009, AAPS PharmSciTech.

[76]  L. Harding,et al.  Understanding the effect of lactose particle size on the properties of DPI formulations using experimental design. , 2009, International journal of pharmaceutics.

[77]  R. Gibson,et al.  Efficacy and safety of inhaled aztreonam lysine for airway pseudomonas in cystic fibrosis. , 2009, Chest.

[78]  V. McDonald,et al.  Nebulised hypertonic saline for cystic fibrosis. , 2009, The Cochrane database of systematic reviews.

[79]  Nazrul Islam,et al.  Dry powder inhalers (DPIs)--a review of device reliability and innovation. , 2008, International journal of pharmaceutics.

[80]  H. Okamoto,et al.  Application of supercritical fluid to preparation of powders of high-molecular weight drugs for inhalation. , 2008, Advanced drug delivery reviews.

[81]  B. Pulliam,et al.  Nanoparticles for drug delivery to the lungs. , 2007, Trends in biotechnology.

[82]  Karen A Robinson,et al.  Cystic fibrosis pulmonary guidelines: chronic medications for maintenance of lung health. , 2007, American journal of respiratory and critical care medicine.

[83]  H. Frijlink,et al.  Dry powder inhalation of colistin in cystic fibrosis patients: a single dose pilot study. , 2007, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[84]  F. Ratjen,et al.  Mucolytics in cystic fibrosis. , 2007, Paediatric respiratory reviews.

[85]  Albert H. L. Chow,et al.  Particle Engineering for Pulmonary Drug Delivery , 2007, Pharmaceutical Research.

[86]  Simon Cawthorne,et al.  Particle engineering techniques for inhaled biopharmaceuticals. , 2006, Advanced drug delivery reviews.

[87]  M. Surette,et al.  Cystic fibrosis: a polymicrobial infectious disease. , 2006, Future microbiology.

[88]  H. Frijlink,et al.  Dry powder inhalers for pulmonary drug delivery , 2004, Expert opinion on drug delivery.

[89]  J. Carlin,et al.  Clinical outcome after early Pseudomonas aeruginosa infection in cystic fibrosis. , 2001, The Journal of pediatrics.

[90]  A. Schoutens,et al.  Deposition of Nacystelyn from a Dry Powder Inhaler in Healthy Volunteers and Cystic Fibrosis Patients , 2001, Drug Development and Industrial Pharmacy.

[91]  L. Kotra,et al.  Aminoglycosides: Perspectives on Mechanisms of Action and Resistance and Strategies to Counter Resistance , 2000, Antimicrobial Agents and Chemotherapy.

[92]  N. Chew,et al.  Effect of particle size, air flow and inhaler device on the aerosolisation of disodium cromoglycate powders. , 2000, International journal of pharmaceutics.

[93]  G P Martin,et al.  The influence of carrier morphology on drug delivery by dry powder inhalers. , 2000, International journal of pharmaceutics.

[94]  P. Sammut,et al.  Effects of standard and high doses of salmeterol on lung function of hospitalized patients with cystic fibrosis , 1999, Pediatric pulmonology.

[95]  P. Benfield,et al.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use. , 1988, Drugs.

[96]  B. Ramsey,et al.  The Changing Face of Cystic Fibrosis , 2020 .

[97]  B. Glick,et al.  Antibiotic resistance in Pseudomonas aeruginosa: mechanisms and alternative therapeutic strategies. , 2019, Biotechnology advances.

[98]  E. Ingenito,et al.  Tezacaftor–Ivacaftor in Patients with Cystic Fibrosis Homozygous for Phe508del , 2017, The New England journal of medicine.

[99]  R. Altman,et al.  PharmGKB summary: ivacaftor pathway, pharmacokinetics/pharmacodynamics , 2017, Pharmacogenetics and genomics.

[100]  S. Nolan,et al.  Dornase alfa for cystic fibrosis. , 2017, Paediatric respiratory reviews.

[101]  C. Goss,et al.  Cystic fibrosis , 2015, Nature Reviews Disease Primers.

[102]  L. Gradon,et al.  Formation of particles for dry powder inhalers , 2014 .

[103]  G. Steinkamp.  [Dry powder inhalers in cystic fibrosis]. , 2014, Pneumologie.

[104]  T. Garg,et al.  Advanced aerosol delivery devices for potential cure of acute and chronic diseases. , 2014, Critical reviews in therapeutic drug carrier systems.

[105]  M. Konstan,et al.  Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: The EAGER trial. , 2011, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

[106]  Hak-Kim Chan,et al.  The role of particle properties in pharmaceutical powder inhalation formulations. , 2002, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[107]  T. Vandamme,et al.  Pulmonary drug delivery systems: recent developments and prospects. , 2002, Critical reviews in therapeutic drug carrier systems.

[108]  G. Crompton,et al.  Dry powder inhalers: advantages and limitations. , 1991, Journal of aerosol medicine : the official journal of the International Society for Aerosols in Medicine.

[109]  E R Weibel,et al.  Morphometry of the human lung: the state of the art after two decades. , 1979, Bulletin europeen de physiopathologie respiratoire.